Specific IgE to cross-reactive carbohydrate determinants strongly affect the in vitro diagnosis of allergic diseases

被引:177
作者
Mari, A
Iacovacci, P
Afferni, C
Barletta, B
Tinghino, R
Di Felice, G
Pini, C
机构
[1] Ist Super Sanita, Dept Immunol, I-00161 Rome, Italy
[2] Natl Hlth Serv, Allergy Unit, Rome, Italy
关键词
allergens; allergy; carbohydrates; cross-reactions; diagnosis; epitopes; glycoproteins; IgE; skin tests;
D O I
10.1016/S0091-6749(99)70171-5
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Cross-reacting carbohydrate determinants (CCDs) are antigenic structures shared by allergenic components from taxonomically distant sources. The case history of a patient with a great discrepancy between skin test and specific IgE results led us to investigate the role of these determinants in his specific case and in an allergic population. Objective: We sought to determine the role of CCDs in causing false-positive and clinically irrelevant results in in vitro tests. Methods: The involvement of CCDs was studied by specific IgE inhibition by using glycoproteins with a known carbohydrate structure. Direct and inhibition assays were performed by commercially available systems, in-house ELISA, and the immunoblotting technique. The binding to the periodate-oxidated carbohydrate structure of glycoproteins and allergenic extracts was also evaluated. A comparative study between skin test and specific IgE responses to the antigens studied was carried out in 428 consecutive allergic subjects. Results: All the tests performed suggested that cross-reacting carbohydrate epitopes were the cause of false-positive specific IgE results in one of the commercial systems and the high reactivity in all the solid-phase in vitro tests. None of the crossreacting carbohydrate allergens yielded a positive skin test response. Periodate treatment caused variable degrees of reduction of IgE binding to the different antigens studied, indicating that CCDs played a different role in each of them. About 41% of patients allergic to pollen had specific IgE for a glycoprotein, without a positive skin test response to the same molecule. Conclusions: CCDs must be taken into account when evaluating the clinical relevance of positive results in in vitro specific IgE assays, at least in the diagnosis of patients with pollen allergy, Commercial systems should be carefully assessed for the ability to detect specific IgE for carbohydrate determinants to avoid false-positive or clinically irrelevant results.
引用
收藏
页码:1005 / 1011
页数:7
相关论文
共 40 条
[1]   IMMUNOGLOBULIN-E ANTIBODIES THAT CROSSREACT WITH VEGETABLE FOODS, POLLEN, AND HYMENOPTERA VENOM [J].
AALBERSE, RC ;
KOSHTE, V ;
CLEMENS, JGJ .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1981, 68 (05) :356-364
[2]   Crossreactive carbohydrate determinants [J].
Aalberse, RC ;
van Ree, R .
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 1997, 15 (04) :375-387
[3]   Arizona cypress (Cupressus arizonica) pollen allergens. Identification of crossreactive periodate-resistant and -sensitive epitopes with monoclonal antibodies [J].
Barletta, B ;
Tinghino, R ;
Corinti, S ;
Afferni, C ;
Iacovacci, P ;
Mari, A ;
Pini, C ;
Di Felice, G .
ALLERGY, 1998, 53 (06) :586-593
[4]   Cross-reactivity between the major allergen from olive pollen and unrelated glycoproteins: Evidence of an epitope in the glycan moiety of the allergen [J].
Batanero, E ;
Villalba, M ;
Monsalve, RI ;
Rodriguez, R .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1996, 97 (06) :1264-1271
[5]  
BINDSLEVJENSEN C, 1997, FOOD ALLERGY ADVERSE, P137
[6]   PRIMARY STRUCTURE OF THE XYLOSE-CONTAINING N-LINKED CARBOHYDRATE MOIETY FROM ASCORBIC-ACID OXIDASE OF CUCURBITA-PEPO-MEDULLOSA [J].
DANDREA, G ;
BOUWSTRA, JB ;
KAMERLING, JP ;
VLIEGENTHART, JFG .
GLYCOCONJUGATE JOURNAL, 1988, 5 (02) :151-157
[7]  
DE CESARE F, 1993, ALLERGY, V48, P248
[8]   RECEIVER OPERATING CHARACTERISTIC ANALYSIS - A USEFUL METHOD FOR A COMPARISON OF THE CLINICAL RELEVANCE OF 2 IN-VITRO IGE TESTS [J].
DEBLAY, F ;
ZANA, H ;
OFFNER, M ;
VEROT, A ;
VELTEN, M ;
PAULI, G .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1993, 92 (02) :255-263
[9]  
ELSHAMI AS, 1989, ADV BIOSCI, V74, P191
[10]  
*EUR DEP QUAL MED, 1997, EUR PHARM, P356